Dr. Julie Brahmer, Johns Hopkins University, discusses the use of biomarker testing and mutational burden to select patients for specific immunotherapies in lung cancer, renal cell carcinoma and melanoma.

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.